CTOs on the Move


 
Cytel enables decision-makers in the life sciences to unlock the full potential of their products. From navigating uncertainty to proving value, Cytel`s 30 years of global expertise in consulting, data-driven analytics, and industry-leading software helps biotech and pharmaceutical companies transform intelligence into confident decisions. We have an uncompromising commitment to scientific rigor and high standards of operational excellence, which are channeled through our locations in North America, Europe, the United Kingdom, and Asia. Together, we enable our clients to deliver the therapies that propel humanity forward.
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million
  • www.cytel.com
  • 950 Winter Street
    Waltham, MA USA 02451
  • Phone: 617.661.2011

Executives

Name Title Contact Details

Similar Companies

Sterling Pharma Solutions

Sterling is a CDMO or contract development and manufacturing organisation (/contract manufacturer organisation) with facilities in the UK and US.

Advanced Pipetting Systems

Advanced Pipetting Systems is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

A and J Consulting Engineering Services, PC

A and J Consulting Engineering Services, PC is a Clifton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BELLWYCK PACKAGING SOLUTIONS

BELLWYCK PACKAGING SOLUTIONS is a Owen Sound, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.